Mesa Laboratories (NASDAQ:MLAB – Get Free Report) is expected to be announcing its Q2 2027 results after the market closes on Thursday, November 5th. Analysts expect Mesa Laboratories to post earnings of $2.29 per share and revenue of $62.20 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.
Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter. The firm had revenue of $60.14 million during the quarter. Mesa Laboratories had a net margin of 1.92% and a return on equity of 22.72%.
Mesa Laboratories Trading Up 1.6%
Shares of NASDAQ:MLAB opened at $131.32 on Thursday. The company has a current ratio of 1.79, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $735.39 million, a PE ratio of 156.34 and a beta of 1.06. Mesa Laboratories has a 1 year low of $69.51 and a 1 year high of $144.35. The firm has a fifty day moving average price of $128.08 and a 200 day moving average price of $103.52.
Mesa Laboratories Announces Dividend
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. Weiss Ratings raised Mesa Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Wall Street Zen raised Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 3rd. Finally, Wells Fargo & Company increased their price objective on Mesa Laboratories from $94.00 to $110.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Three research analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Mesa Laboratories has an average rating of “Hold” and an average target price of $110.00.
Check Out Our Latest Research Report on Mesa Laboratories
Insider Activity
In other news, CEO Siddhartha Kadia purchased 7,093 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were bought at an average price of $112.80 per share, with a total value of $800,090.40. Following the completion of the transaction, the chief executive officer directly owned 7,093 shares in the company, valued at $800,090.40. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Sullivan sold 7,093 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $112.80, for a total transaction of $800,090.40. Following the completion of the sale, the director owned 17,834 shares of the company’s stock, valued at $2,011,675.20. The trade was a 28.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 2.80% of the company’s stock.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company’s offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.
Mesa Laboratories’ product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings.
See Also
- Five stocks we like better than Mesa Laboratories
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
